• Founded: 2011
  • Location: Gaithersburg, MD
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2
  • Therapy area: AML/MDS
  • Drug types: ONC, IMM, INF
  • Lead product: NEXI-001
  • Product link:
  • Funding: $126.5M IPO Feb 2021; $23M A Jan 2018

job board

Short description:

Artificially engineered antigen-presenting cells

Drug notes:

Also Clin0 multiple cancers; NEXI-002 Clin1 (paused Aug 2022) multiple myeloma, Clin0 autoimmune diseases; NEXI-003 Clin0/Clin1 HPV cancers, Clin0 infectious diseases; NEXI-004 Clin0 EBV diseases

Long description:

Contact us to add description:


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy